Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Iyer, Abishek ^a   Kauter, Kathleen ^b   Alam, Md Ashraful ^a   Hwang, Sung Hee ^c   Morisseau, Christophe ^c   Hammock, Bruce D ^c   Brown, Lindsay ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (3 ADAMANTAN 1 YLUREIDO) CYCLOHEXYLOXY] BENZOIC ACID; EPOXIDE HYDROLASE; GLUCOSE; HEPARIN; HYDROLASE INHIBITOR; INSULIN; LIPID; PENTOBARBITAL; UNCLASSIFIED DRUG; 4 (4 (3 ADAMANTAN 1 YLUREIDO)CYCLOHEXYLOXY)BENZOIC ACID; 4-(4-(3-ADAMANTAN-1-YLUREIDO)CYCLOHEXYLOXY)BENZOIC ACID; BENZOIC ACID DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE DIET; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE MODEL; ENZYME INHIBITION; HEART FUNCTION; IN VIVO STUDY; LIPID DIET; LIVER DYSFUNCTION; MACRONUTRIENT; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SYSTOLIC BLOOD PRESSURE; WISTAR RAT; ADIPOSE TISSUE; ANIMAL; BLOOD; CARDIOVASCULAR SYSTEM; DIET; DRUG ANTAGONISM; FAT INTAKE; GLUCOSE BLOOD LEVEL; LIVER; PANCREAS; PATHOLOGY; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; BENZOIC ACIDS; BLOOD GLUCOSE; CARDIOVASCULAR SYSTEM; DIET; DIETARY CARBOHYDRATES; DIETARY FATS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; LIPIDS; LIVER; MALE; METABOLIC SYNDROME X; PANCREAS; RATS; RATS, WISTAR; UREA;

EID: 84855181094     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/758614     Document Type: Article

References (42)

1. Iyer A., Fairlie D. P., Prins J. B., Hammock B. D., Brown L., Inflammatory lipid mediators in adipocyte function and obesity Nature Reviews Endocrinology 2010 6 2 71 82
2. Iyer A., Brown L., Lipid mediators and inflammation in glucose intolerance and insulin resistance Drug Discovery Today: Disease Mechanisms 2010 7 3-4 e191 e197
3. Potenza M. V., Mechanick J. I., The metabolic syndrome: definition, global impact, and pathophysiology Nutrition in Clinical Practice 2009 24 5 560 577
4. Simmons R. K., Alberti K. G., Gale E. A., Colagiuri S., Tuomilehto J., Qiao Q., Ramachandran A., Tajima N., Brajkovich Mirchov I., Ben-Nakhi A., Reaven G., Hama Sambo B., Mendis S., Roglic G., The metabolic syndrome: useful concept or clinical tool? Report of a WHO expert consultation Diabetologia 2010 53 4 600 605
5. van Gaal L. F., Mertens I. L., De Block C. E., Mechanisms linking obesity with cardiovascular disease Nature 2006 444 7121 875 880 (Pubitemid 46028447)
6. Reaven G. M., Role of insulin resistance in human disease Diabetes 1988 37 12 1595 1607 (Pubitemid 19004941)
7. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R., Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation Circulation 2005 111 11 1448 1454 (Pubitemid 40396812)
8. Zimmet P. Z., Alberti K. G., Shaw J. E., Mainstreaming the metabolic syndrome: a definitive defenition Medical Journal of Australia 2005 183 4 175 176 (Pubitemid 41150321)
9. Ferrannini E., Is insulin resistance the cause of the metabolic syndrome? Annals of Medicine 2006 38 1 42 51 (Pubitemid 43177787)
10. Symonds M. E., Sebert S. P., Hyatt M. A., Budge H., Nutritional programming of the metabolic syndrome Nature Reviews Endocrinology 2009 5 11 604 610
11. Habenicht A. H., Salbach P., Goerig M., Zeh W., Janssen-Timmen U., Blattner C., King W. C., Glomset J. A., The LDL receptor pathway delivers arachidonic acid for eicosanoid formation in cells stimulated by platelet-derived growth factor Nature 1990 345 6276 634 636
12. Kudo I., Murakami M., Phospholipase A2 enzymes Prostaglandins and Other Lipid Mediators 2002 68-69 3 58
13. Lambeau G., Gelb M. H., Biochemistry and physiology of mammalian secreted phospholipases A 2 Annual Review of Biochemistry 2008 77 495 520
14. Shi X., Ding M., Dong Z., Chen F., Ye J., Wang S., Leonard S. S., Castranova V., Vallyathan V., Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF- B activation, and TNF- production Molecular and Cellular Biochemistry 1999 199 1-2 93 102 (Pubitemid 29476147)
15. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z. W., Karin M., Shoelson S. E., Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk Science 2001 293 5535 1673 1677 (Pubitemid 32807849)
16. Bastard J. P., Maachi M., Lagathu C., Kim M. J., Caron M., Vidal H., Capeau J., Feve B., Recent advances in the relationship between obesity, inflammation, and insulin resistance European Cytokine Network 2006 17 1 4 12
17. Imig J. D., Hammock B. D., Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases Nature Reviews Drug Discovery 2009 8 10 794 805
18. Inceoglu B., Wagner K., Schebb N. H., Morisseau C., Jinks S. L., Ulu A., Hegedus C., Rose T., Brosnan R., Hammock B. D., Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP Proceedings of the National Academy of Sciences of the United States of America 2011 108 12 5093 5097
19. Imig J. D., Zhao X., Zaharis C. Z., Olearczyk J. J., Pollock D. M., Newman J. W., Kim I. H., Watanabe T., Hammock B. D., An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension Hypertension. 2005 46 4 975 981
20. Chiamvimonvat N., Ho C. M., Tsai H. J., Hammock B. D., The soluble epoxide hydrolase as a pharmaceutical target for hypertension Journal of Cardiovascular Pharmacology 2007 50 3 225 237 (Pubitemid 47428969)
21. Loch D., Hoey A., Morisseau C., Hammock B. O., Brown L., Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase Cell Biochemistry and Biophysics 2007 47 1 87 97 (Pubitemid 46570701)
22. Liu J. Y., Tsai H. J., Hwang S. H., Jones P. D., Morisseau C., Hammock B. D., Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation British Journal of Pharmacology 2009 156 2 284 296
23. Panchal S. K., Poudyal H., Iyer A., Nazer R., Alam A., Diwan V., Kauter K., Sernia C., Campbell F., Ward L., Gobe G., Fenning A., Brown L., High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats Journal of Cardiovascular Pharmacology 2011 57 1 611 624
24. Iyer A., Brown L., Fermented wheat germ extract (Avemar) in the treatment of cardiac remodeling and metabolic symptoms in rats Evidence-Based Complementary and Alternative Medicine 2011 1 10
25. Iyer A., Fenning A., Lim J., Le G. T., Reid R. C., Halili M. A., Fairlie D. P., Brown L., Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats: research paper British Journal of Pharmacology 2010 159 7 1408 1417
26. Chan V., Fenning A., Iyer A., Hoey A., Brown L., Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats Current Pharmaceutical Biotechnology 2011 12 3 429 436
27. Litwin S. E., Katz S. E., Morgan J. P., Douglas P. S., Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat Circulation 1994 89 1 345 354 (Pubitemid 24026509)
28. Imig J. D., Zhao X., Capdevila J. H., Morisseau C., Hammock B. D., Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension Hypertension 2002 39 2 690 694 (Pubitemid 34165207)
29. de Taeye B. M., Morisseau C., Coyle J., Covington J. W., Luria A., Yang J., Murphy S. B., Friedman D. B., Hammock B. B., Vaughan D. E., Expression and regulation of soluble epoxide hydrolase in adipose tissue Obesity 2010 18 3 489 498
30. Seubert J. M., Sinal C. J., Graves J., Degraff L. M., Bradbury J. A., Lee C. R., Goralski K., Carey M. A., Luria A., Newman J. W., Hammock B. D., Falck J. R., Roberts H., Rockman H. A., Murphy E., Zeldin D. C., Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function Circulation Research 2006 99 4 442 450 (Pubitemid 44253701)
31. Zeldin D. C., Foley J., Boyle J. E., Moomaw C. R., Tomer K. B., Parker C., Steenbergen C., Wu S., Predominant expression of an arachidonate epoxygenase in islets of langerhans cells in human and rat pancreas Endocrinology 1997 138 3 1338 1346 (Pubitemid 27089795)
32. Falck J. R., Manna S., Moltz J., Chacos N., Capdevila J., Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets Biochemical and Biophysical Research Communications 1983 114 2 743 749 (Pubitemid 13030721)
33. Luo P., Chang H. H., Zhou Y., Zhang S., Hwang S. H., Morisseau C., Wang C. Y., Inscho E. W., Hammock B. D., Wang M. H., Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis Journal of Pharmacology and Experimental Therapeutics 2010 334 2 430 438
34. Luria A., Bettaieb A., Xi Y., Shieh G.-J., Liu H.-C., Inoue H., Tsai H.-J., Imig J. D., Haj F. G., Hammock B. D., Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance Proceedings of the National Academy of Sciences of the United States of America 2011 108 22 9038 9043
35. Lee C. R., North K. E., Bray M. S., Fornage M., Seubert J. M., Newman J. W., Hammock B. D., Couper D. J., Heiss G., Zeldin D. C., Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study Human Molecular Genetics 2006 15 10 1640 1649 (Pubitemid 43904830)
36. Burdon K. P., Lehtinen A. B., Langefeld C. D., Carr J. J., Rich S. S., Freedman B. I., Herrington D., Bowden D. W., Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study Diabetes and Vascular Disease Research 2008 5 2 128 134 (Pubitemid 351839285)
37. Yang J., Schmelzer K., Georgi K., Hammock B. D., Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry Analytical Chemistry 2009 81 19 8085 8093
38. Morisseau C., Inceoglu B., Schmelzer K., Tsai H. J., Jinks S. L., Hegedus C. M., Hammock B. D., Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids Journal of Lipid Research 2010 51 12 3481 3490
39. Moghaddam M. F., Grant D. F., Cheek J., Greene J. F., Williamson K. C., Hammock B. D., Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase Nature Medicine 1997 3 5 562 566 (Pubitemid 27198657)
40. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H. J., Kim I. H., Tuteja D., Mateo R. K. P., Singapuri A., Davis B. B., Low R., Hammock B. D., Chiamvimonvat N., Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors Proceedings of the National Academy of Sciences of the United States of America 2006 103 49 18733 18738 (Pubitemid 44913479)
41. Schmelzer K. R., Kubala L., Newman J. W., Kim I.-H., Eiserich J. P., Hammock B. D., Soluble epoxide hydrolase is a therapeutic target for acute inflammation Proceedings of the National Academy of Sciences of the United States of America 2005 102 28 9772 9777 (Pubitemid 40993644)
42. Liu J. Y., Yang J., Inceoglu B., Qiu H., Ulu A., Hwang S. H., Chiamvimonvat N., Hammock B. D., Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model Biochemical Pharmacology 2010 79 6 880 887